Angiogenesis in hematologic malignancies

被引：98

作者：

Moehler, TM

Ho, AD

Goldschmidt, H

Barlogie, B

机构：

[1] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany

[2] Univ Arkansas Med Sci, Inst Res & Therapy, Little Rock, AR 72205 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2003年 / 45卷 / 03期

关键词：

angiogenesis; vasculogenesis; leukemia; lymphoma; multiple myeloma;

D O I：

10.1016/S1040-8428(02)00135-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is defined as the formation of new capillaries from preexisting blood vessels and plays an important role in the progression of solid tumors. Recently a similar relationship has been described in several hematologic malignancies. Expression of the angiogenic peptides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor correlates with clinical characteristics in leukemia and non-Hodgkin's-lymphoma and the serum/plasma concentrations serve as predictors of poor prognosis. Increased bone marrow microvessels in multiple myeloma (MM) are correlated with decreased overall survival. Thalidomide which has antiangiogenic effects and direct cytotoxic effects was found to be effective in MM, myelodysplastic syndrome and acute myeloid leukemia (AML). Preliminary data indicate activity of VEGF-tyrosine kinase inhibitors in AML. Clinical research is now aimed at testing antiangiogenic treatment strategies in several hematologic neoplasms as well as identifying the best candidate patients for specific approaches. (C) 2002 Published by Elsevier Science Ireland Ltd.

引用

收藏

页码：227 / 244

页数：18

相关论文

共 191 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].

Aguayo, A ;

Estey, E ;

Kantarjian, H ;

Mansouri, T ;

Gidel, C ;

Keating, M ;

Giles, F ;

Estrov, Z ;

Barlogie, B ;

Albitar, M .

BLOOD, 1999, 94 (11) :3717-3721

[3] Molecular mechanisms of lymphangiogenesis in health and disease [J].

Alitalo, K ;

Carmeliet, P .

CANCER CELL, 2002, 1 (03) :219-227

[4] Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas [J].

Aoki, Y ;

Tosato, G .

BLOOD, 1999, 94 (12) :4247-4254

[5] Reactive oxygen generated by Nox1 triggers the angiogenic switch [J].

Arbiser, JL ;

Petros, J ;

Klafter, R ;

Govindajaran, B ;

McLaughlin, ER ;

Brown, LF ;

Cohen, C ;

Moses, M ;

Kilroy, S ;

Arnold, RS ;

Lambeth, JD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :715-720

[6] Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors [J].

Avet-Loiseau, H ;

Gerson, F ;

Magrangeas, F ;

Minvielle, S ;

Harousseau, JL ;

Bataille, R .

BLOOD, 2001, 98 (10) :3082-3086

[7]

Avramis IA, 2001, ANTICANCER RES, V21, P2281

[8] Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia [J].

Bairey, O ;

Zimra, Y ;

Shaklai, M ;

Rabizadeh, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :400-406

[9] Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].

Banks, RE ;

Forbes, MA ;

Kinsey, SE ;

Stanley, A ;

Ingham, E ;

Walters, C ;

Selby, PJ .

BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964

[10] Soluble IL-6Rα upregulates IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells [J].

Barillé, S ;

Collette, M ;

Thabard, W ;

Bleunven, C ;

Bataille, R ;

Amiot, M .

CYTOKINE, 2000, 12 (09) :1426-1429

← 1 2 3 4 5 6 7 8 9 10 →